Biopartners biosimilar rhGH Valtropin yields encouraging Ph III data

Baar, Switzerland-based biosimilars specialist Biopartners says that its recombinant human growth hormone (rhGH) Valtropin has demonstrated equivalent safety and efficacy to its reference product. According to the firm, this will be welcomed by industry observers concerned about the safety of biosimilars (see pages 24-25). The randomized, double-blind, Phase III investigation was carried out in Europe, South Africa and the USA, and assessed Valtropin's efficacy and safety in treatment-naive children with growth hormone deficiency. The results will be published in the September issue of Hormone Research, Biopartners said.